Advertisement
New Zealand markets closed

  • NZX 50

    12,457.41
    -34.17 (-0.27%)
     

  • NZD/USD

    0.6342
    +0.0013 (+0.20%)
     

  • NZD/EUR

    0.5675
    +0.0018 (+0.31%)
     

  • ALL ORDS

    8,476.80
    +14.00 (+0.17%)
     

  • ASX 200

    8,212.20
    +8.50 (+0.10%)
     

  • OIL

    68.64
    +0.97 (+1.43%)
     

  • GOLD

    2,680.80
    -14.10 (-0.52%)
     

  • NASDAQ

    20,008.62
    -106.91 (-0.53%)
     

  • FTSE

    8,320.76
    +35.85 (+0.43%)
     

  • Dow Jones

    42,313.00
    +137.89 (+0.33%)
     

  • DAX

    19,473.63
    +235.27 (+1.22%)
     

  • Hang Seng

    20,632.30
    +707.72 (+3.55%)
     

  • NIKKEI 225

    39,829.56
    +903.93 (+2.32%)
     

  • NZD/JPY

    90.1570
    -1.4180 (-1.55%)
     

Karyopharm to Participate at Upcoming Investor Conferences

PR Newswire
·2-min read

NEWTON, Mass., Sept. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:

(PRNewsfoto/Karyopharm Therapeutics Inc.)
(PRNewsfoto/Karyopharm Therapeutics Inc.)

H.C. Wainwright 26th Annual Global Investment Conference
Format: Podium presentation
Date: Tuesday, September 10, 2024
Time: 9:00 a.m. ET

Baird 2024 Global Healthcare Conference
Format: Fireside chat
Date: Wednesday, September 11, 2024
Time: 10:50 a.m. ET

A live webcast of these events, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-302235059.html

SOURCE Karyopharm Therapeutics Inc.